VINCERE BIOSCIENCES INC

Cambridge, MA · Biotech · Private

Small molecule USP30 inhibitors for Parkinson's disease targeting the parkin-USP30 mitophagy pathway

vincerebio.com →
Grants
$1.7M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
8
2 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Discovery and Development of USP30 inhibitors as Disease-Modifying Therapy for Parkinson's disease.$251,987
Federal grantDepartment of Health and Human Services · Phase I · Evaluation of USP30 small molecule inhibitors in models relevant to Cardiac Aging$299,497
Federal grantDepartment of Health and Human Services · Phase I · In vivo Evaluation of USP30 Inhibitors in Models Relevant to Parkinson's Disease$470,514
Federal grantDepartment of Health and Human Services · Phase I · In vivo Evaluation of USP30 Inhibitors in Models Relevant to Parkinson's Disease$470,514
Federal grantDepartment of Health and Human Services · Phase I · In vivo Evaluation of USP30 Inhibitors in Models Relevant to Parkinson's Disease$228,711
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2918Propeller Bio——
2919EICOSIS LLC——
2920PARION SCIENCES, INC.——
2921VINCERE BIOSCIENCES INC——
2922AADI, LLC——
2923NAUTILUS, INC.——
2924CULNEXIN THERAPEUTICS LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 8
  • USP30 Inhibitors And Uses Thereofgranted
  • USP30 Inhibitors And Uses Thereofapplication
  • USP30 Inhibitors And Uses Thereofgranted
  • USP30 Inhibitors And Uses Thereofapplication
  • USP30 Inhibitors And Uses Thereofapplication
  • USP30 Inhibitors And Uses Thereofapplication
  • USP30 Inhibitors And Uses Thereofapplication
  • USP30 Inhibitors And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.